Table 3 Demographic data and radiological results of the two study groups before treatment
Variables | Number, percentage, median (IQR) | P value | |
|---|---|---|---|
MTX only group (n = 80) | MTX and doxycycline group (n = 80) | ||
Age (years) | 47 (42.3–52.8) | 46 (39.25–52) | 0.8 |
Disease duration (years) | 4.5 (2–6) | 4 (0.5–5.75) | 0.079 |
Disease duration classification | |||
Early (≤ 6 months) | 15 (18.8%) | 24 (30%) | 0.09 |
Established (< 6 months) | 65 (81.3%) | 56 (70%) | |
Sex | |||
Male | 2 (2.5%) | 8 (10%) | 0.06 |
Female | 78 (97.5%) | 72 (90%) | |
NSAIDs users | |||
Yes | 58 (72.5%) | 50 (62.5%) | 0.177 |
No | 22 (27.5%) | 30 (37.5%) | |
Steroids users | |||
Yes | 28 (35%) | 32 (40%) | 0.514 |
No | 52 (65%) | 48 (60%) | |
DAS28 categories | |||
Remission | 0 | 0 | 0.98 |
Mild | 10 (12.5%) | 10 (12.5%) | |
Moderate | 34 (42.5%) | 33 (41.3%) | |
High | 36 (45%) | 37 (46.3%) | |
DAS28-CRP | 4.9 (3.8–6.4) | 4.9 (3.8–5.6) | 0.67 |
Larsen score | 20 (12–38.5) | 20 (8–38.75) | 0.6 |